Main Management ETF Advisors LLC bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,880 shares of the company's stock, valued at approximately $706,000.
Several other large investors have also bought and sold shares of the company. Zacks Investment Management lifted its holdings in shares of Krystal Biotech by 5.6% during the third quarter. Zacks Investment Management now owns 9,447 shares of the company's stock valued at $1,720,000 after purchasing an additional 504 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Krystal Biotech by 15.1% during the 3rd quarter. Wellington Management Group LLP now owns 12,680 shares of the company's stock valued at $2,308,000 after acquiring an additional 1,660 shares during the last quarter. State Street Corp grew its holdings in Krystal Biotech by 9.0% in the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company's stock valued at $264,455,000 after buying an additional 119,936 shares during the last quarter. Hilltop Holdings Inc. acquired a new stake in Krystal Biotech in the 3rd quarter valued at approximately $209,000. Finally, Erste Asset Management GmbH acquired a new stake in Krystal Biotech in the 3rd quarter valued at approximately $3,224,000. Institutional investors own 86.29% of the company's stock.
Krystal Biotech Trading Up 3.1 %
Shares of KRYS traded up $5.49 during mid-day trading on Friday, reaching $185.25. The company's stock had a trading volume of 216,765 shares, compared to its average volume of 229,305. Krystal Biotech, Inc. has a 1-year low of $101.34 and a 1-year high of $219.34. The stock has a market cap of $5.33 billion, a P/E ratio of 104.66 and a beta of 0.80. The business has a 50-day simple moving average of $181.27 and a two-hundred day simple moving average of $184.63.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company's revenue was up 879.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.67) EPS. Research analysts anticipate that Krystal Biotech, Inc. will post 2.97 EPS for the current year.
Wall Street Analyst Weigh In
A number of brokerages have commented on KRYS. Citigroup raised their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. William Blair upgraded Krystal Biotech to a "strong-buy" rating in a research report on Friday, August 30th. Evercore ISI lifted their target price on Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a research note on Monday, August 12th. HC Wainwright reaffirmed a "buy" rating and set a $221.00 price objective on shares of Krystal Biotech in a research note on Tuesday, November 5th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Krystal Biotech in a research note on Thursday, August 29th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Krystal Biotech currently has a consensus rating of "Buy" and a consensus target price of $202.29.
Read Our Latest Stock Analysis on KRYS
Insider Activity at Krystal Biotech
In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the transaction, the insider now directly owns 1,500,882 shares of the company's stock, valued at approximately $296,814,424.32. This trade represents a 1.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 14.10% of the stock is currently owned by company insiders.
About Krystal Biotech
(
Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Further Reading
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
